Digipharm - outcomes based contracting made easy (#3080)

Creation
Draft
Initial
Detailed
Accepted
Adoption
Idea Description
Overview of Innovation:
Representative model or prototype system developed & can be effectively evaluated. International patent pending.

We use blockchain technology & smart contracts to automate outcomes based contracting in a trusted fashion for pharmaceuticals, devices & healthcare services.

Digipharm have developed a platform to utilise revolutionary blockchain technology to overcome barriers to the execution of innovative pricing agreements. Our system reduces admin costs associated with reconciling value-based pricing agreements for all stakeholders through the use of smart contracts & creates a medical information infrastructure that is tamper-proof & immutable, something that is imperative when paying for performance versus a fee for service approach. We aim to accelerate the much-needed restructuring of healthcare delivery systems to a value-based approach on a fully independent, third party platform. This will provide the opportunity to evaluate the real time performance & value provided by therapies in a real-life setting without the current infrastructural limitations.

Our solution will address current delivery challenges such as:
  1. Inability to track patient adherence in real time
  2. Inconsistent practices between healthcare providers
  3. Patient privacy concerns
  4. Manual process handling - claims validation, credit not creation, adjustment calculation
  5. Inability to use a ‘fit for all’ customisable platform across all regions
  6. The admin burden of processing pricing agreements, fragmented health systems & data accessibility act as major barriers to the required restructuring of health systems
  7. Empower payers & manufacturers to negotiate meticulous pricing agreements, from truly personalised schemes based on surrogate outcomes to wider access agreements applicable to patient cohorts of interest
  8. Allowing patients to be followed & aggregates data related to patient treatment & outcomes across numerous sites
  9. Expediting integration, coordination & delivery of patient centric healthcare systems with a focus on improving patient outcomes
  10. Allowing automated dynamic pricing models to be implemented across different indications, patient subgroups, therapy lines & localities while providing consistent & comparable outputs
  11. Delays in access to life saving medicines
Benefits to the NHS - see attached

We have started our UK pilot & are finalising our pilot in Ireland. We need to create the right processes for good information governance & seek to partner & work with the NHS in order to implement our platforms.
Similar Content2
Innovation 'Elevator Pitch':
We use blockchain technology and smart contracts to automate outcomes based contracting in a trusted fashion for pharmaceuticals, devices and healthcare services.
 
Overview of Innovation:
Digipharm have developed a platform to utilise revolutionary blockchain technology to overcome barriers to the execution of innovative pricing agreements. Our system reduces administrative costs associated with reconciling value-based pricing agreements for all stakeholders through the use of smart contracts and creates a medical information infrastructure that is tamper-proof and immutable, something that is imperative when paying for performance versus a fee for service approach. We aim to accelerate the much-needed restructuring of healthcare delivery systems to a value-based approach on a fully independent, third party platform. This will provide the opportunity to evaluate the real time performance and value provided by therapies in a real-life setting without the current infrastructural limitations.

 The Digipharm solution will address current delivery challenges such as:
  1. Inability to track patient adherence in real time.
  2. Inconsistent practices between healthcare providers.
  3. Patient privacy concerns.
  4. Manual process handling - claims validation, credit not creation, adjustment calculation.
  5. Inability to use a ‘fit for all’ customisable platform across all regions
  6. The administrative burden of processing pricing agreements, fragmented health systems and data accessibility act as major barriers to the required restructuring of health systems.
  7.  Empower payers and manufacturers to negotiate meticulous pricing agreements, ranging from truly personalised schemes based on surrogate outcomes to wider access agreements applicable to patient cohorts of interest.
  8. Allowing patients to be followed, and aggregates data related to patient treatment and outcomes across numerous sites.
  9. Expediting integration, coordination and delivery of patient centric healthcare systems with a focus on improving patient outcomes.
  10. Allowing automated dynamic pricing models to be implemented across different indications, patient subgroups, therapy lines and localities while providing consistent and comparable outputs.
  11. Delays in access to life saving medicines.

 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Clinical trials and evidence / Digital health / Innovation and adoption / Person centred care
Benefit to NHS:
Currently, the payer is experiencing unsustainable levels of expenditure within a fragmented, inefficient and unnecessarily costly healthcare system. As a result, payers are less willing to carry the ‘risk’ or ‘uncertainty’ of purchasing and providing costly therapies or services. These challenges can lead to delays for patients in accessing much needed medication, restricted use to specific patients only and funding for the drug not being approved. The Digipharm solution will give the payer the opportunity to engage with the manufacturer or service provider and share the risk by offering innovative pricing models. This solution relies on a predetermined set of tangible or measurable patient-related outcomes that are defined by interested parties. The solution will also provide the payer with real world evidence to ensure only cost-effective medications/services are being prescribed.
It will also address the administrative burden which is currently a huge barrier in reconciling outcomes based contracts.
Providers will be able to offer patients an optimal basket of therapies while also being rewarded for providing better care. 

the blockchain platform gives all contracting parties the opportunitie to observe outcomes as they are collected. This helps decision making at both the patient level but also at population level.
Initial Review Rating
4.60 (1 ratings)
Benefit to WM population:
The patient will have quicker access to life saving medications which will enhance the chances of experiencing optimal health outcomes. It will also facilitate personalised and patient centric healthcare.

longer term, outcomes based healthcare reimbursement can reduce expenditure while improving outcomes thus having long-lasting impact on wellbeing and productivity.
Current and planned activity: 
We have started our UK pilot. We are finalising our pilot in Ireland. We need to create the right processes for good information governance, We seek to partner and work with the NHS in order to implement our platforms.
What is the intellectual property status of your innovation?:
international patent pending
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
2 years
Ease of scalability: 
Simple
Rejection Reason:
Submitted to a wrong campaign
Read more
Hide details
Innovation 'Elevator Pitch':
Future-proof blockchain based provenance solution for CGT. Our digital service creates an efficient & transparent chain of identity/custody/condition & diagnostic, address compliance burdens, reduce cost & enable co-operation in a competitive arena.
Overview of Innovation:
FarmaTrust have used blockchain to create a tracking service for the latest cell & gene therapies.

Our solution is a working prototype that is able to track chain of identity, custody, condition and diagnostic for autologous cell therapies. It ensures transparency for regulators, enables efficiency by reducing HIPAA compliance requirements and records are ultimately more secure. All with the ultimate aim to support improved patient outcomes.

We also believe that the blockchain will be a key enabler in decentralising the manufacturing process to ultimately take these new therapies closer to the patient.

Because of this we are developing significant knowledge and skill based on these new technologies for the digitised healthcare and medicines agenda, and specifically in the smart and connected logistics supply chain that are applicable globally, thereby making the UK the go to place for this type of expertise.

View the FarmaTrust Explainer Infographic – click here.

 
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Advanced diagnostics, genomics and precision medicine / Clinical trials and evidence / Digital health
Benefit to NHS:
The features of our solution will provide the following benefits:
  • A foundational system that is interoperable with the multitude of hardware and software systems which are used in many healthcare settings around the world, including the NHS
  • By ensuring data integrity between the various systems, scanners and data input devices without having to make substantial integration changes
  • By creating efficiencies through automating payment processes, regulatory reporting, compliance and audit
  • By utilising blockchain with AI to mine data collected in order to maximise cost savings and delivering improved services with the same budget or less
  • By providing a truly connected and smart data collection system across the multiple stakeholders to benefit the research teams, NHS, regulators and ultimately patients
  • By providing a real alternative way to do things differently to the traditional legacy cloud-based technologies that will start to struggle with the increasingly digital future of healthcare and medicines/devices
  • By leveraging the innate properties of blockchain to enable effective co-operation between competing CGT manufacturers
  • Enabling future readiness for a world that moves from the current increasingly resource hungry and inefficient supply chain model to a decentralised efficient (on) demand driven chain reality!
                                                                 
Initial Review Rating
3.80 (1 ratings)
Benefit to WM population:
Our Innovation will:
  • Develop an effective and robust CGT supply chain solution for any research team in the WM involved in CGT development, eg Midlands & Wales ATTC
  • Expose and eliminate inconsistencies and errors, thereby give therapy quality assurance to WM researchers and patients involved in trials
  • Have the potential to remove product loss completely from the high value supply chain
  • Support on outcome based value proposition for precision medicines and high value therapies based on blockchain smart contracts
  • Be interoperable with blockchain advances, incumbent cloud technology providers and the latest IoT sensors used in the WM – less money spent on tech integration and more spent on patient care
  • Leverage machine learning for data analytics which provides predictive and prescriptive insights to allow greater efficiency, cost saving and demand planning for supply logistics
  • Help make the WM and the UK a global thought leader for blockchain (enabled by Internet of Things and Artificial Intelligence) developed healthcare services!
Current and planned activity: 
We have a working solution that is:
  • Already available through our US partner. As of late 2018 Systech One are white labelling and marketing our linear small molecule supply chain solution in the US and Europe. Systech One powered by FarmaTrust!
  • A fully working blockchain based needle to needle tracking solution prototype as a result of a significant commercial partnership with a German cell & gene therapy solution provider.
  • Creating increasing interest with the Innovate UK Catapults. Namely the Digital Catapult, Cell & Gene Therapy Catapult and Centre for Process Innovation.
  • Going to be a pilot in a province of Mongolia as commissioned by their Govt – this will be our small molecule linear track and trace solution
  • Going to provide track and trace services for medicinal cannabis plants. Work that has been commissioned by Peterson One for the Thai Govt
We are also working with a senior Oncologist from Birmingham to spec our new clinical trial tracking solution.
What is the intellectual property status of your innovation?:
Core IP belongs to FarmaTrust.
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
1 year
Ease of scalability: 
3
Read more
Hide details
0
0
Votes
-99999

Created by

Share and Follow